Alendronate Prevents Further Bone Loss in Renal Transplant Recipients
Open Access
- 1 November 2001
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 16 (11) , 2111-2117
Abstract
The aim of this study was to investigate the effects of alendronate, calcitriol, and calcium in bone loss after kidney transplantation. We enrolled 40 patients (27 men and 13 women, aged 44.2 ± 11.6 years) who had received renal allograft at least 6 months before (time since transplant, 61.2 ± 44.6 months). At baseline, parathyroid hormone (PTH) was elevated in 53% of the patients and the Z scores for bone alkaline phosphatase (b‐ALP) and urinary type I collagen cross‐linked N‐telopeptide (u‐NTX) were higher than expected (p < 0.001). T scores for the lumbar spine (−2.4 ± 1.0), total femur (−2.0 ± 0.7), and femoral neck (−2.2 ± 0.6) were reduced (p < 0.001). After the first observation, patients were advised to adhere to a diet containing 980 mg of calcium daily and their clinical, biochemical, and densitometric parameters were reassessed 1 year later. During this period, bone density decreased at the spine (−2.6 ± 5.7%; p < 0.01), total femur (−1.4 ± 4.2%; p < 0.05), and femoral neck (−2.0 ± 3.0%; p < 0.001). Then, the patients were randomized into two groups: (1) group A—10 mg/day of alendronate, 0.50 μg/day of calcitriol, and 500 mg/day of calcium carbonate; and (2) group B—0.50 μg/day of calcitriol and 500 mg/day of calcium carbonate. A further metabolic and densitometric reevaluation was performed after the 12‐month treatment period. At the randomization time, group A and group B patients did not differ as to the main demographic and clinical variables. After treatment, bone turnover markers showed a nonsignificant fall in group B patients, while both b‐ALP and u‐NTX decreased significantly in alendronate‐treated patients. Bone density of the spine (+5.0 ± 4.4%), femoral neck (+4.5 ± 4.9%), and total femur (+3.9 ± 2.8%) increased significantly only in the alendronate‐treated patients. However, no trend toward further bone loss was noticed in calcitriol and calcium only treated subjects. No drug‐related major adverse effect was recorded in the two groups. We conclude that renal transplanted patients continue to loose bone even in the long‐term after the graft. Alendronate normalizes bone turnover and increases bone density. The association of calcitriol to this therapy seems to be advantageous for better controlling the complex abnormalities of skeletal metabolism encountered in these subjects.Keywords
This publication has 28 references indexed in Scilit:
- Pamidronate therapy as prevention of bone loss following renal transplantationKidney International, 2000
- Effect of Calcitriol on Bone Loss After Cardiac or Lung TransplantationJournal of Bone and Mineral Research, 2000
- Alendronate for the Treatment of Osteoporosis in MenNew England Journal of Medicine, 2000
- Cross-Sectional Analysis of Renal Transplantation OsteoporosisJournal of Bone and Mineral Research, 1999
- Increased Risk of Fracture in Patients Receiving Solid Organ TransplantsJournal of Bone and Mineral Research, 1999
- Continuous and cyclical clodronate therapies and bone density in postmenopausal bone lossObstetrics & Gynecology, 1996
- Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal studyAmerican Journal of Kidney Diseases, 1996
- Post-transplantation bone disease: The role of immunosuppressive agents and the skeletonJournal of Bone and Mineral Research, 1996
- BONE MINERAL DENSITY AFTER KIDNEY TRANSPLANTATIONTransplantation, 1995
- Pamidronate Reduces PTH-mediated bone loss in a gene transfer model of hyperparathyroidism in ratsJournal of Bone and Mineral Research, 1991